{"id":1886,"date":"2025-02-21T08:00:25","date_gmt":"2025-02-21T13:00:25","guid":{"rendered":"https:\/\/9bio.ca\/?p=1886"},"modified":"2026-01-20T09:25:24","modified_gmt":"2026-01-20T14:25:24","slug":"9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline","status":"publish","type":"post","link":"https:\/\/9biotx.com\/fr\/news\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/","title":{"rendered":"9Bio Th\u00e9rapeutiques obtient un financement strat\u00e9gique pour faire progresser son pipeline en oncologie"},"content":{"rendered":"<p><strong>Qu\u00e9bec, le 21 f\u00e9vrier 2025<\/strong> \u2013 9Bio Th\u00e9rapeutiques, une entreprise de biotechnologie sp\u00e9cialis\u00e9e dans les th\u00e9rapies oncologiques de nouvelle g\u00e9n\u00e9ration, annonce sa participation \u00e0 une initiative de 2 M$ men\u00e9e en partenariat avec CQDM, IVADO et deux entreprises qu\u00e9b\u00e9coises. Ce financement permettra d\u2019acc\u00e9l\u00e9rer le d\u00e9veloppement pr\u00e9clinique de th\u00e9rapies anticanc\u00e9reuses hautement cibl\u00e9es et plus s\u00fbres, en s\u2019appuyant sur l\u2019intelligence artificielle (IA) et la biologie structurale pour r\u00e9inventer la d\u00e9couverte de m\u00e9dicaments.<\/p>\n\n\n\n<p>L\u2019initiative b\u00e9n\u00e9ficie d\u2019une subvention de 1 M$ du gouvernement du Qu\u00e9bec, octroy\u00e9e par le biais du programme Partenar-IA du CQDM, en partenariat avec IVADO.<\/p>\n\n\n\n<p>Ce financement permettra \u00e0 9Bio Th\u00e9rapeutiques, Molecular Forecaster et Aramis Biotechnologies de renforcer leurs plateformes respectives :<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>9Bio Th\u00e9rapeutiques exploitera sa plateforme de biologie structurale guid\u00e9e par l\u2019IA pour concevoir des anticorps hautement s\u00e9lectifs destin\u00e9s aux applications en oncologie.<\/li>\n\n\n\n<li>Molecular Forecaster utilisera son approche biophysique, renforc\u00e9e par des mod\u00e8les d\u2019apprentissage automatique, pour g\u00e9n\u00e9rer de petites mol\u00e9cules ciblant sp\u00e9cifiquement les cellules tumorales.<\/li>\n\n\n\n<li>Aramis Biotechnologies produira les anticorps \u00e0 l\u2019aide de sa plateforme versatile de production dans les plantes.<\/li>\n<\/ul>\n\n\n\n<p>Bien que cette collaboration rassemble des expertises compl\u00e9mentaires, chaque entreprise conservera l\u2019int\u00e9gralit\u00e9 de sa propri\u00e9t\u00e9 intellectuelle, garantissant un \u00e9quilibre entre d\u00e9veloppement collaboratif et cr\u00e9ation de valeur ind\u00e9pendante.<\/p>\n\n\n\n<p>\u00ab Ce partenariat acc\u00e9l\u00e8re notre vision d\u2019exploiter l\u2019IA et la biologie structurale pour une nouvelle g\u00e9n\u00e9ration de th\u00e9rapies contre le cancer. Nous ne faisons pas que raccourcir les d\u00e9lais de d\u00e9couverte ; nous d\u00e9veloppons des m\u00e9dicaments con\u00e7us pour maximiser l\u2019efficacit\u00e9 tout en minimisant les effets secondaires, au b\u00e9n\u00e9fice des patients \u00bb, affirme Henrique de Carvalho, Co-fondateur et PDG, 9Bio Th\u00e9rapeutiques.<\/p>\n\n\n\n<p style=\"font-size:26px\"><strong>Une avanc\u00e9e vers l\u2019avenir des th\u00e9rapies en oncologie<\/strong><\/p>\n\n\n\n<p>Les traitements oncologiques actuels entra\u00eenent souvent des effets secondaires importants, poussant jusqu\u2019\u00e0 32 % des patients \u00e0 interrompre leur traitement ou \u00e0 opter pour des alternatives moins efficaces (1). Cette collaboration vise \u00e0 d\u00e9velopper des th\u00e9rapies de pr\u00e9cision de nouvelle g\u00e9n\u00e9ration, am\u00e9liorant les r\u00e9sultats pour les patients tout en maximisant la viabilit\u00e9 commerciale et l\u2019expansion du pipeline.<\/p>\n\n\n\n<p style=\"font-size:26px\"><strong>Positionner 9Bio pour une croissance rapide en innovation oncologique<\/strong><\/p>\n\n\n\n<p>La plateforme de biologie structurale guid\u00e9e par l\u2019IA de 9Bio surmonte les principales limites des th\u00e9rapies biologiques existantes, permettant :<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Une r\u00e9duction du ciblage hors tumeur, minimisant les effets secondaires<\/li>\n\n\n\n<li>Une am\u00e9lioration de la biodisponibilit\u00e9, renfor\u00e7ant l\u2019efficacit\u00e9 th\u00e9rapeutique<\/li>\n\n\n\n<li>L\u2019exploration de nouvelles modalit\u00e9s th\u00e9rapeutiques, ouvrant la voie \u00e0 de nouvelles options de traitement<\/li>\n<\/ul>\n\n\n\n<p>\u00ab En int\u00e9grant la biologie structurale assist\u00e9e par l\u2019IA \u00e0 la mod\u00e9lisation mol\u00e9culaire avanc\u00e9e, 9Bio transforme la conception des biologiques en oncologie. Notre technologie permet d\u2019ing\u00e9nier des mol\u00e9cules th\u00e9rapeutiques ciblant s\u00e9lectivement les tumeurs tout en r\u00e9duisant les effets hors cible, r\u00e9pondant ainsi \u00e0 un d\u00e9fi majeur en canc\u00e9rologie \u201d, mentionne Philipe Gobeil, Co-fondateur, Pr\u00e9sident et CSO, 9Bio Th\u00e9rapeutiques.<\/p>\n\n\n\n<p class=\"has-theme-palette-9-color has-text-color has-link-color wp-elements-6e728912ec13a547080eebd361e9dfa9\">Lisez le communiqu\u00e9 officiel du CQDM <a href=\"https:\/\/cqdm.org\/nouvelles-et-evenements\/le-cqdm-ivado-et-trois-entreprises-quebecoises-investissent-2m-pour-accelerer-le-developpement-de-therapies-anticancereuses-hautement-ciblees-et-moins-toxiques-grace-a-lia\/\" data-type=\"link\" data-id=\"https:\/\/cqdm.org\/en\/news-and-events\/cqdm-ivado-and-three-quebec-based-companies-invest-2m-to-accelerate-the-development-of-highly-targeted-less-toxic-cancer-therapies-using-ai\/\" target=\"_blank\" rel=\"noreferrer noopener\"><u>ici<\/u><\/a>.<\/p>\n\n\n\n<p class=\"has-theme-palette-9-color has-text-color has-link-color wp-elements-db2c221a627fb28da75a0206b79b9276\"><strong>R\u00e9f\u00e9rence : &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/strong><br><a>(1) Holmstroem et al., Eur J. Cancer, 2024<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><\/p>\n\n\n\n<p class=\"has-theme-palette-9-color has-text-color has-link-color wp-elements-34fb7e385f2793a0b67080e0802dd753\"><strong>\u00c0 propos de 9Bio Th\u00e9rapeutiques<\/strong><br><br>9Bio est une entreprise de biotechnologie d\u00e9di\u00e9e au d\u00e9veloppement de th\u00e9rapies oncologiques innovantes. Notre plateforme de biologie structurale guid\u00e9e par l'IA int\u00e8gre des contextes anatomiques et biochimiques pour concevoir des m\u00e9dicaments ciblant s\u00e9lectivement les tumeurs. Gr\u00e2ce \u00e0 cette approche, nous d\u00e9veloppons des traitements sp\u00e9cifiquement dirig\u00e9s contre les tumeurs, tout en pr\u00e9servant les tissus sains, am\u00e9liorant ainsi la s\u00e9curit\u00e9, l\u2019efficacit\u00e9 et ouvrant la voie \u00e0 des modalit\u00e9s th\u00e9rapeutiques jusqu\u2019ici sous-exploit\u00e9es. Notre pipeline comprend deux th\u00e9rapies en phase de d\u00e9couverte : un conjugu\u00e9 anticorps-m\u00e9dicament (ADC) ciblant les cellules tumorales chimior\u00e9sistantes et un autre ADC ciblant les cellules immunitaires subverties par les tumeurs.<\/p>\n\n\n\n<p class=\"has-theme-palette-9-color has-text-color has-link-color wp-elements-a685e0bc96ba7d43c04fe73c8af28d76\"><strong>\u00c0 propos de Biotechnologies Aramis<\/strong><br><br>Bas\u00e9e \u00e0 Qu\u00e9bec, Aramis Biotechnologies est une entreprise canadienne fond\u00e9e en 2023 qui se sp\u00e9cialise dans la production de vaccins innovants produits dans les plantes. En tant qu\u2019entreprise \u00e0 capital majoritairement d\u00e9tenu par nos employ\u00e9s-actionnaires, l\u2019ambition d\u2019Aramis est de d\u00e9velopper des solutions novatrices et durables pour r\u00e9pondre aux d\u00e9fis de sant\u00e9 publique actuels et futurs. L'\u00e9quipe d'Aramis est reconnaissante du soutien apport\u00e9 par Innovation, Sciences et D\u00e9veloppement \u00e9conomique Canada, par la Ville de Qu\u00e9bec et par son groupe d\u2019investisseurs priv\u00e9s. Pour en savoir plus, <a href=\"https:\/\/aramisbiotechnologies.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/aramisbiotechnologies.com\/<\/a>.<\/p>\n\n\n\n<p><strong>\u00c0 propos du CQDM<\/strong><\/p>\n\n\n\n<p class=\"has-text-align-left has-theme-palette-9-color has-text-color has-link-color wp-elements-cf91edc9372a360d9722ed0d4526bad2\"><em>Facilitateur d\u2019innovation biopharma<br><\/em>Le CQDM est un consortium de recherche biopharmaceutique \u00e0 but non lucratif dont la mission est de soutenir et de faciliter la recherche et d\u00e9veloppement collaborative multipartite visant \u00e0 acc\u00e9l\u00e9rer la translation ou la transformation de technologies innovantes en solutions r\u00e9pondant \u00e0 des besoins m\u00e9dicaux non satisfaits, tout en g\u00e9n\u00e9rant des retomb\u00e9es significatives pour l\u2019\u00e9conomie qu\u00e9b\u00e9coise et canadienne. Pour plus d\u2019informations, consultez le site web&nbsp; <a href=\"https:\/\/www.cqdm.org\">https:\/\/www.cqdm.org<\/a> et rejoignez-nous sur Twitter\/X <a href=\"https:\/\/x.com\/CQDM_Canada\" target=\"_blank\" rel=\"noreferrer noopener\">@CQDM_Canada<\/a> et <a href=\"https:\/\/www.linkedin.com\/company\/cqdm\/\" target=\"_blank\" rel=\"noreferrer noopener\">LinkedIn.<\/a> <\/p>\n\n\n\n<p><strong>Partenar-IA <\/strong>est un programme de soutien direct aux entreprises qu\u00e9b\u00e9coises pour la r\u00e9alisation de projets de R-D biopharmaceutique collaborative fond\u00e9s sur l\u2019intelligence artificielle et applicables au secteur biopharmaceutique.<\/p>\n\n\n\n<p><strong>\u00c0 propos d\u2019IVADO<\/strong><\/p>\n\n\n\n<p class=\"has-theme-palette-9-color has-text-color has-link-color wp-elements-16267adb614d63239d9728b8abc57b16\">IVADO est un consortium interdisciplinaire et intersectoriel de recherche, de formation et de mobilisation des connaissances qui a pour mission de b\u00e2tir et de promouvoir une intelligence artificielle robuste, raisonnante et responsable. Pilot\u00e9 par l\u2019Universit\u00e9 de Montr\u00e9al, avec 4 partenaires universitaires (Polytechnique Montr\u00e9al, HEC Montr\u00e9al, Universit\u00e9 Laval et Universit\u00e9 McGill), IVADO rassemble des centres de recherches, des partenaires gouvernementaux et industriels, pour coconstruire des initiatives intersectorielles ambitieuses favorisant un changement de paradigme de l\u2019IA et de son adoption. Pour plus d\u2019informations, consultez le site web <a href=\"https:\/\/ivado.ca\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/ivado.ca\/<\/a>.<\/p>\n\n\n\n<p class=\"has-theme-palette-9-color has-text-color has-link-color wp-elements-e302e7e42809f6bb471cf7517726bf78\"><strong>\u00c0 propos de Molecular Forecaster<\/strong><br><br>Molecular Forecaster Inc. (MFI) aide les organisations \u00e0 prendre des d\u00e9cisions plus judicieuses en mati\u00e8re de conception de m\u00e9dicaments \u00e0 base de petites mol\u00e9cules. MFI utilise un service de recherche hautement collaboratif pour transformer les donn\u00e9es en connaissances afin d'acc\u00e9l\u00e9rer les programmes pharmaceutiques pr\u00e9cliniques dans le monde entier. L'entreprise est un partenaire de choix dans la conception de m\u00e9dicaments \u00e0 base de petites mol\u00e9cules, combinant des outils et des technologies exclusifs, une expertise et un savoir-faire, ainsi qu'une approche globale de la collaboration afin de ne faire avancer que les meilleurs coups au but. Pour en savoir plus, consultez <a href=\"https:\/\/molecularforecaster.com\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/molecularforecaster.com\/fr\/<\/a><a id=\"_msocom_2\"><\/a><\/p>\n\n\n\n<p><\/p>","protected":false},"excerpt":{"rendered":"<p>9Bio Th\u00e9rapeutiques annonce sa participation \u00e0 une initiative de 2 M$ men\u00e9e en partenariat avec CQDM, IVADO et deux entreprises qu\u00e9b\u00e9coises. Ce financement permettra d\u2019acc\u00e9l\u00e9rer le d\u00e9veloppement pr\u00e9clinique de th\u00e9rapies anticanc\u00e9reuses hautement cibl\u00e9es et plus s\u00fbres, en s\u2019appuyant sur l\u2019intelligence artificielle (IA) et la biologie structurale pour r\u00e9inventer la d\u00e9couverte de m\u00e9dicaments.<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_EventAllDay":false,"_EventTimezone":"","_EventStartDate":"","_EventEndDate":"","_EventStartDateUTC":"","_EventEndDateUTC":"","_EventShowMap":false,"_EventShowMapLink":false,"_EventURL":"","_EventCost":"","_EventCostDescription":"","_EventCurrencySymbol":"","_EventCurrencyCode":"","_EventCurrencyPosition":"","_EventDateTimeSeparator":"","_EventTimeRangeSeparator":"","_EventOrganizerID":[],"_EventVenueID":[],"_OrganizerEmail":"","_OrganizerPhone":"","_OrganizerWebsite":"","_VenueAddress":"","_VenueCity":"","_VenueCountry":"","_VenueProvince":"","_VenueState":"","_VenueZip":"","_VenuePhone":"","_VenueURL":"","_VenueStateProvince":"","_VenueLat":"","_VenueLng":"","_VenueShowMap":false,"_VenueShowMapLink":false,"_kadence_starter_templates_imported_post":false,"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-1886","post","type-post","status-publish","format-standard","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>9Bio Therapeutics secures strategic funding to advance its oncology pipeline - 9Bio Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/9biotx.com\/fr\/news\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"9Bio Therapeutics secures strategic funding to advance its oncology pipeline - 9Bio Therapeutics\" \/>\n<meta property=\"og:description\" content=\"9Bio Therapeutics is pleased to announce its participation in a $2M project initiative alongside CQDM, IVADO, and two Quebec-based biotech companies. This funding will accelerate the preclinical development of highly targeted, safer cancer therapies, leveraging artificial intelligence (AI) and structural biology to redefine drug discovery.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/9biotx.com\/fr\/news\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"9Bio Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-21T13:00:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-20T14:25:24+00:00\" \/>\n<meta name=\"author\" content=\"Henrique de Carvalho\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Henrique de Carvalho\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\\\/\"},\"author\":{\"name\":\"Henrique de Carvalho\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#\\\/schema\\\/person\\\/eda3764256a793b2350112b46b0169a8\"},\"headline\":\"9Bio Therapeutics secures strategic funding to advance its oncology pipeline\",\"datePublished\":\"2025-02-21T13:00:25+00:00\",\"dateModified\":\"2026-01-20T14:25:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\\\/\"},\"wordCount\":814,\"publisher\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#organization\"},\"articleSection\":[\"News\"],\"inLanguage\":\"fr-CA\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\\\/\",\"url\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\\\/\",\"name\":\"9Bio Therapeutics secures strategic funding to advance its oncology pipeline - 9Bio Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#website\"},\"datePublished\":\"2025-02-21T13:00:25+00:00\",\"dateModified\":\"2026-01-20T14:25:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/9biotx.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"9Bio Therapeutics secures strategic funding to advance its oncology pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#website\",\"url\":\"https:\\\/\\\/9biotx.com\\\/\",\"name\":\"9Bio Therapeutics\",\"description\":\"Engineering Biological Possibilities\",\"publisher\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/9biotx.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#organization\",\"name\":\"9Bio Therapeutics\",\"url\":\"https:\\\/\\\/9biotx.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/9biotx.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/9Bio-therapeutics-transparent-background-tangerine-small.png\",\"contentUrl\":\"https:\\\/\\\/9biotx.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/9Bio-therapeutics-transparent-background-tangerine-small.png\",\"width\":200,\"height\":80,\"caption\":\"9Bio Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/9bio\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#\\\/schema\\\/person\\\/eda3764256a793b2350112b46b0169a8\",\"name\":\"Henrique de Carvalho\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g\",\"caption\":\"Henrique de Carvalho\"},\"sameAs\":[\"https:\\\/\\\/9bio.ca\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"9Bio Therapeutics secures strategic funding to advance its oncology pipeline - 9Bio Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/9biotx.com\/fr\/news\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/","og_locale":"fr_CA","og_type":"article","og_title":"9Bio Therapeutics secures strategic funding to advance its oncology pipeline - 9Bio Therapeutics","og_description":"9Bio Therapeutics is pleased to announce its participation in a $2M project initiative alongside CQDM, IVADO, and two Quebec-based biotech companies. This funding will accelerate the preclinical development of highly targeted, safer cancer therapies, leveraging artificial intelligence (AI) and structural biology to redefine drug discovery.","og_url":"https:\/\/9biotx.com\/fr\/news\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/","og_site_name":"9Bio Therapeutics","article_published_time":"2025-02-21T13:00:25+00:00","article_modified_time":"2026-01-20T14:25:24+00:00","author":"Henrique de Carvalho","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Henrique de Carvalho","Estimation du temps de lecture":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/#article","isPartOf":{"@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/"},"author":{"name":"Henrique de Carvalho","@id":"https:\/\/9biotx.com\/#\/schema\/person\/eda3764256a793b2350112b46b0169a8"},"headline":"9Bio Therapeutics secures strategic funding to advance its oncology pipeline","datePublished":"2025-02-21T13:00:25+00:00","dateModified":"2026-01-20T14:25:24+00:00","mainEntityOfPage":{"@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/"},"wordCount":814,"publisher":{"@id":"https:\/\/9biotx.com\/#organization"},"articleSection":["News"],"inLanguage":"fr-CA"},{"@type":"WebPage","@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/","url":"https:\/\/9biotx.com\/news\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/","name":"9Bio Therapeutics secures strategic funding to advance its oncology pipeline - 9Bio Therapeutics","isPartOf":{"@id":"https:\/\/9biotx.com\/#website"},"datePublished":"2025-02-21T13:00:25+00:00","dateModified":"2026-01-20T14:25:24+00:00","breadcrumb":{"@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/9biotx.com\/news\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/9biotx.com\/"},{"@type":"ListItem","position":2,"name":"9Bio Therapeutics secures strategic funding to advance its oncology pipeline"}]},{"@type":"WebSite","@id":"https:\/\/9biotx.com\/#website","url":"https:\/\/9biotx.com\/","name":"9Bio Th\u00e9rapeutiques","description":"Engineering Biological Possibilities","publisher":{"@id":"https:\/\/9biotx.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/9biotx.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/9biotx.com\/#organization","name":"9Bio Th\u00e9rapeutiques","url":"https:\/\/9biotx.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/9biotx.com\/#\/schema\/logo\/image\/","url":"https:\/\/9biotx.com\/wp-content\/uploads\/2024\/10\/9Bio-therapeutics-transparent-background-tangerine-small.png","contentUrl":"https:\/\/9biotx.com\/wp-content\/uploads\/2024\/10\/9Bio-therapeutics-transparent-background-tangerine-small.png","width":200,"height":80,"caption":"9Bio Therapeutics"},"image":{"@id":"https:\/\/9biotx.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/9bio\/"]},{"@type":"Person","@id":"https:\/\/9biotx.com\/#\/schema\/person\/eda3764256a793b2350112b46b0169a8","name":"Henrique de Carvalho","image":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/secure.gravatar.com\/avatar\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g","caption":"Henrique de Carvalho"},"sameAs":["https:\/\/9bio.ca"]}]}},"taxonomy_info":{"category":[{"value":1,"label":"News"}]},"featured_image_src_large":false,"author_info":{"display_name":"Henrique de Carvalho","author_link":"https:\/\/9biotx.com\/fr\/news\/author\/decarvalho\/"},"comment_info":0,"category_info":[{"term_id":1,"name":"News","slug":"news","term_group":0,"term_taxonomy_id":1,"taxonomy":"category","description":"9Bio News","parent":0,"count":7,"filter":"raw","cat_ID":1,"category_count":7,"category_description":"9Bio News","cat_name":"News","category_nicename":"news","category_parent":0}],"tag_info":false,"_links":{"self":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/posts\/1886","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/comments?post=1886"}],"version-history":[{"count":6,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/posts\/1886\/revisions"}],"predecessor-version":[{"id":1991,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/posts\/1886\/revisions\/1991"}],"wp:attachment":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/media?parent=1886"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/categories?post=1886"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/tags?post=1886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}